A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- 08 Aug 2018 Status changed from not yet recruiting to recruiting.
- 13 Jul 2018 Planned initiation date changed from 25 May 2018 to 1 Aug 2018.
- 18 May 2018 New trial record